Experts from BRG recently discussed the two presidential candidates' stances on key healthcare issues, including drug pricing ...

Suki, a company offering AI voice solutions to healthcare companies, has secured $70 million in Series D funding, it announced Thursday. The financing will help the company build new products.

Shortly after releasing a scathing interim report in July that revealed how three players dominate the pharmacy benefit manager market and raise drug costs for patients, the Federal Trade ...

The conundrum of American health care has become all too familiar: While spending outpaces other high-income countries, our quality of care often lags our peers – demonstrating no real ...

Advancements in surgical technology and therapeutics have improved outcomes for many cancer patients, resulting in 18 million survivors (and growing). New and more efficacious cancer drugs are ...

The 2024 election is nearing the corner and has major implications for the healthcare industry, from abortion to drug pricing. During the Reuters Total Health Conference held in Chicago on Tuesday ...

Bipartisan Congressional scrutiny has shone a harsh spotlight on the many tactics used by pharmacy benefit managers (PBMs) and Big Pharma that contribute to the sky high costs of prescription ...

The healthcare industry is on the cusp of a transformation similar to that witnessed by the banking industry 15 to 20 years ago. Like healthcare, banking is a very personal yet highly regulated ...

Neuroscience drug developer Lundbeck is expanding its scope to epilepsy via the $2.6 billion acquisition of Longboard Pharmaceuticals, a company whose lead asset is in late-stage clinical ...

Schizophrenia is currently treated with older medications with limited efficacy and troublesome side effects that lead many patients to stop taking them. The FDA has approved a novel Bristol Myers ...

The fee-for-service (FFS) payment model that has been the norm in healthcare for decades may finally be on its way out, with many physicians and hospital leaders leaning into value-based care (VBC).

Asthma patients have many drug options, but many patients find these choices either inconvenient or inadequate for severe cases of the chronic respiratory condition. Upstream Bio is pursuing a ...